This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
The substantial data supporting platelet-rich plasma (PRP) therapy and exosomes for androgenic alopecia have yet to convince the FDA that they deserve regulatory approval.
Medscape Medical News